ALL
Conference Coverage
Highly effective in Ph-negative B-cell ALL: Hyper-CVAD with sequential blinatumomab
Conference Coverage
COVID-19–related outcomes poor for patients with hematologic disease in ASH registry
From the Journals
‘Impressive’ outcomes sans chemo in poor-prognosis ALL
Conference Coverage
Immunotherapy for ALL: Roles emerge in R/R disease, MRD+ disease
“Another very exciting development is that these immunotherapies are now demonstrating efficacy and increased tolerability over chemotherapy in...
Conference Coverage
Are HMAS appropriate for posttransplant maintenance in acute leukemias?
Not yet, hematologist/oncologist tells colleagues at ALF meeting.
From the Journals
Study: Complications from childhood ALL and its treatment are common, but can be managed
From the Journals
Orthopedic problems in children can be the first indication of acute lymphoblastic leukemia
Conference Coverage
Survey quantifies COVID-19’s impact on oncology
Oncologists detail how COVID-19 has impacted care, caregivers, continuing medical education, and clinical trials.
Conference Coverage
TKI choice key for fit/unfit patients with Ph+ALL
Ponatinib (Iclusig) is associated with high response rates in combination therapy, but toxicities may be too great for less fit patients.
From the Journals
CSF metabolomic profile linked to cancer-related fatigue in children with ALL
From the Journals
Polygenic risk score may predict VTE in adolescents, but not adults, with ALL